Saturday, July 11, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Patents matching “anti-”

1,068 pharma patents match "anti-" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 1,068
Index total 30,257
Page 13 / 45

Quick answer

This filtered view shows 1,068 pharmaceutical patents matching "anti-" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

1,068 results for “anti-” · 30,257 patents in full index Clear search

  1. US 11542312

    IL-2 superagonists in combination with anti-PD-1 antibodies

    Medicenna Therapeutics Inc. · Granted Jan 3, 2023 · Expires Dec 29, 2042

    granted

  2. US 11542326

    Anti-IL-25 antibodies and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Jan 3, 2023 · Expires Dec 29, 2042

    granted

  3. US 11542317

    Anti-VEGF protein compositions and methods for producing the same

    REGENERON PHARMACEUTICALS, INC. · Granted Jan 3, 2023 · Expires Dec 29, 2042

    granted

  4. US 11534430

    Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs

    Lutonix, Inc. · Granted Dec 27, 2022 · Expires Dec 22, 2042

    granted

  5. US 11529312

    Francisella lipids as broad anti-inflammatory therapeutics and associated methods of use

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Dec 20, 2022 · Expires Dec 15, 2042

    granted

  6. US 11525001

    Anti-CD8 antibodies and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Dec 13, 2022 · Expires Dec 8, 2042

    granted

  7. US 11524017

    Method of using substrates of AKR1B1/AKR1B10 as anti-cancer drugs

    Beijing Normal University Hong Kong Baptist University United International College · Granted Dec 13, 2022 · Expires Dec 8, 2042

    granted

  8. US 11524053

    Methods and compositions for treatment of angiogenic disorders using anti-VEGF agents

    The Regents of the University of California · Granted Dec 13, 2022 · Expires Dec 8, 2042

    granted

  9. US 11519020

    Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF

    REGENERON PHARMACEUTICALS, INC. · Granted Dec 6, 2022 · Expires Dec 1, 2042

    granted

  10. US 11517606

    Composition having anti-glycation effect and application thereof

    INFINITUS (CHINA) COMPANY LTD. · Granted Dec 6, 2022 · Expires Dec 1, 2042

    granted

  11. US 11518818

    Therapeutic anti-IgE antibodies and methods and compositions thereof

    The Regents of the University of California · Granted Dec 6, 2022 · Expires Dec 1, 2042

    granted

  12. US 11511001

    Radiolabeled anti-LAG3 antibodies for immuno-PET imaging

    REGENERON PHARMACEUTICALS, INC. · Granted Nov 29, 2022 · Expires Nov 24, 2042

    granted

  13. US 11505593

    Anti-VEGF protein compositions and methods for producing the same

    REGENERON PHARMACEUTICALS, INC. · Granted Nov 22, 2022 · Expires Nov 17, 2042

    granted

  14. US 11505594

    Anti-VEGF protein compositions and methods for producing the same

    REGENERON PHARMACEUTICALS, INC. · Granted Nov 22, 2022 · Expires Nov 17, 2042

    granted

  15. US 11498963

    Anti-LILRB antibodies and their use in detecting and treating cancer

    The Board of Regents of the University of Texas System · Granted Nov 15, 2022 · Expires Nov 10, 2042

    granted

  16. US 11492392

    Polynucleotides encoding anti-C5 antibodies

    REGENERON PHARMACEUTICALS, INC. · Granted Nov 8, 2022 · Expires Nov 3, 2042

    granted

  17. US 11484591

    Chemoprevention using controlled-release formulations of anti-interleukin 6 agents, synthetic vitamin A analogues or metabolites, and estradiol metabolites

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Nov 1, 2022 · Expires Oct 27, 2042

    granted

  18. US 11485770

    Anti-VEGF protein compositions and methods for producing the same

    REGENERON PHARMACEUTICALS, INC. · Granted Nov 1, 2022 · Expires Oct 27, 2042

    granted

  19. US 11485793

    Anti-MUC16 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind MUC16 and CD3, and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Nov 1, 2022 · Expires Oct 27, 2042

    granted

  20. US 11479602

    Methods of treating C5-associated diseases comprising administering anti-C5 antibodies

    REGENERON PHARMACEUTICALS, INC. · Granted Oct 25, 2022 · Expires Oct 20, 2042

    granted

  21. US 11471443

    Anti-flavivirus compounds and methods of use

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Oct 18, 2022 · Expires Oct 13, 2042

    granted

  22. US 11472812

    Anti-cancer compounds targeting Ral GTPases and methods of using the same

    The Regents of the University of Colorado, a Body Corporate · Granted Oct 18, 2022 · Expires Oct 13, 2042

    granted

  23. US 11464801

    Compositions and methods for treating cancer with anti-CD33 immunotherapy

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Oct 11, 2022 · Expires Oct 6, 2042

    granted

  24. US 11459373

    Anti-VEGF protein compositions and methods for producing the same

    REGENERON PHARMACEUTICALS, INC. · Granted Oct 4, 2022 · Expires Sep 29, 2042

    granted

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.